Publisher: S. Karger AG | 2003-05 | ISBN: 380557536X | Pages: 292 | PDF | 6.1 MB
Numerous investigators hit institute accumulated levels of cyclooxygenase-2 (COX-2) in both pre-malignant and cancerous tissues. Moreover, animals engineered to be COX-2 nonstandard or aerated with a selective COX-2 inhibitor showed low ontogeny manufacture and growth. The inform aggregation reviews these findings suggesting that COX-2 is a legal molecular direct for the hindrance and communication of cancer. The prototypal chapters are devoted to the epidemiology of nonsteroidal anti-inflammatory drugs (NSAIDs) and cancer, the medicine of COX-2 inhibitors and the conception of COX-2 countenance in manlike cancers. Besides, the aggregation contains a program of chapters examining the unification between COX-2 and cancer in limited meat (e.g. skin, breast, cervix, digestive tract, lung, etc.). Furthermore, individual clinical trials assessing the possibleness of COX-2 inhibitors for preventing and treating cancer are described.
http://avaxhome.ws/ebooks/Cox_2_A_New_Target_for_Cancer_Prevention_and_Treatment.html